IMA Clinical Research Adds Devana Solutions’ PROPEL Clinical Trial Data Platform

Bringing the Clinical Trial Site to the Patient: IMA Clinical Research Adds Devana Solutions’ PROPEL Clinical Trial Data Platform


While 2021 certainly had its ups and downs, the Devana Solutions team is delighted to say we were able to end the year with a BANG! This past year we focused on accelerating clinical trials through the power of connectivity and data through our new PROPEL Enterprise technology. With the pandemic accelerating the shift to decentralized clinical trials, the PROPEL platform became an invaluable asset to our larger research organization clients. Devana PROPEL is leveraging the cloud to connect central research operations professionals with site-based clinicians and staff for real-time clinical trial collaboration. In short, Devana Solutions is bringing the clinical trial site to the patient. 

Today, Devana Solutions is pleased to announce IMA Clinical Research has made the commitment to adopt the most innovative site operations and analytics platform in the clinical trials industry, Devana PROPEL. “Partnering with Devana Solutions aligns with IMA Clinical Research’s centralization strategy initiated to improve efficiency within our network and accelerate study startup, supporting our mission of advancing the development of novel treatments to patients in need,” said IMA Group CEO & President, Mark Weinberger, Ph.D., MPH. 

With a rapidly growing network of traditional site locations, over 100 satellite sites and a database of over 300,000 patients, IMA Clinical Research represents the ideal client-profile to adopt Devana PROPEL Enterprise. “We are thrilled to welcome IMA Clinical Research onto our PROPEL platform,” commented Barry Lake, Devana Solutions’ CEO and Co-Founder. “They truly are a perfect fit for our technology which uses the power of the cloud to bring the expertise of clinical trials professionals into the diverse community site locations where IMA Clinical Research excels. Their broadly distributed site network allows millions of genetically, socially and racially diverse patient populations in urban centers and underserved locations to access clinical trials as a care option.” 

Patient access to clinical trials and research professionals leveraging advanced technology shouldn’t be limited by geography. They won’t, thanks to cloud-based platforms like Devana Solutions PROPEL and IMA Clinical Research. Stay tuned for a steady stream of new Devana Solutions client-partnership announcements in 2022! 


About Devana Solutions

Decentralized clinical trials and work-from-anywhere is now a reality. Devana Solutions innovative cloud platform supports real-time collaboration between central research operations professionals and decentralized clinicians serving patients in diverse communities. Devana even bridges the technology access and data divide by seamlessly and securely connecting decentralized researchers to other mission-critical clinical trials systems. From pipeline administration to rapid study startup automation. From document-sharing through the capture, display, analysis, and exchange of key trial performance metrics data from central research leaders to decentralized trial teams. From investigative site to CRO to trial sponsor, Devana Solutions is the answer. At Devana Solutions, we’re transforming the business of clinical trials. 

About IMA Clinical Research

IMA Clinical Research, a division of The IMA Group, is a physician-founded network of integrated clinical research sites specializing in Phase II-IV clinical trials in multiple therapeutic areas. IMA Clinical Research offers a flexible delivery model for site-based, hybrid and fully decentralized trials through its network of dedicated research clinics, a nationwide array of 100 satellite sites and a rapidly-growing database of over 300,000 patients.  We provide centralized processes for contracting, regulatory, training and patient recruitment ensuring rapid start-up, efficient enrollment and high-quality delivery across our network. For more information visit or